Affiliation:
1. Vanderbilt University Medical Center
2. VUMC
3. University of Michigan
Abstract
Abstract
Circulating metabolites act as biomarkers of dysregulated metabolism, and may inform disease pathophysiology. A portion of the inter-individual variability in circulating metabolites is influenced by common genetic variation. We evaluated whether a genetics-based “virtual” metabolomics approach can identify novel metabolite-disease associations. We examined the association between polygenic scores for 726 metabolites (derived from OMICSPRED) with 1,247 clinical phenotypes in 57,735 European ancestry and 15,754 African ancestry participants from the BioVU DNA Biobank. We probed significant relationships through Mendelian randomization (MR) using genetic instruments constructed from the METSIM Study, and validated significant MR associations using independent GWAS of candidate phenotypes. We found significant associations between 336 metabolites and 168 phenotypes in European ancestry and 107 metabolites and 56 phenotypes among African ancestry. Of these metabolite-disease pairs, MR analyses confirmed associations between 73 metabolites and 53 phenotypes in European ancestry. Of 22 metabolite-phenotype pairs evaluated for replication in independent GWAS, 16 were significant (false discovery rate p<0.05). Validated findings included the metabolites bilirubin and X–21796 with cholelithiasis, phosphatidylcholine(16:0/22:5n3,18:1/20:4) and arachidonate(20:4n6) with inflammatory bowel disease and Crohn's disease, and campesterol with coronary artery disease and myocardial infarction. These associations may represent biomarkers or potentially targetable mediators of disease risk.
Publisher
Research Square Platform LLC
Reference61 articles.
1. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Accessed September 29, 2017. https://data.globalchange.gov/report/national-diabetes-statistics-report-estimates-diabetes-its-burden
2. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association;Mozaffarian D;Circulation,2016
3. Economic costs of diabetes in the U.S. in 2012;American Diabetes Association;Diabetes Care,2013
4. Inborn variation in metabolism;Mootha VK;Nat Genet,2010
5. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community;Lieb W;Open Heart,2018